The Get Baked bakery in Leeds, England had to temporarily shut down after it was found to be using illegal sprinkles imported from the US.
The US-made sprinkles contain E127 food coloring, which can't be used in the UK other than in cocktail cherries and candied cherries.
The Trading Standards inspector had told Get Baked owner Rich Myers that a customer reported the use of illegal sprinkles, prompting the inspection.
Myers buys the imported sprinkles from a wholesaler in the UK as local sprinkles aren't as good.
The prohibition on the use of the imported sprinkles could seriously impact Myers' shop, a small independent business that only has a small menu, as it won’t be able to sell their best-selling cookies.
The US Food and Drug Administration approved E127 for use in 1969, saying it "may be safely used for coloring foods generally."


Cambodia King Pardons Opposition Leader Kem Sokha After Treason Conviction
SQM Q1 Profit More Than Doubles as Lithium Prices Surge
Judge Dismisses Trump Administration Lawsuit Against Boston Sanctuary City Policy
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion
Universal Music Group Rejects Pershing Square Takeover Proposal
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand
Boeing Wins Fraud Lawsuit Over 737 MAX Filed by LOT Polish Airlines
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
DOJ Opens Criminal Investigation Into E. Jean Carroll Over Alleged Perjury
ICC Pressure Mounts as Families of Duterte Drug War Victims Demand Justice
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 



